Prevalence of AmpC and other β-lactamases in enterobacteria at a large urban university hospital in Brazil

Diagnostic Microbiology and Infectious Disease

Volumn 60, Issue 1, 2008, Pages 79-87

  da Silva Dias, Rubens Clayton ^a   Borges Neto, Armando Alves ^a   D'Almeida Ferraiuoli, Giovanna Ianini ^a   de Oliveira, Márcia P ^a   Riley, Lee W ^b   Moreira, Beatriz Meurer ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AmpC lactamase; Enterobacteria; ESBL; Hodge test; Multidrug resistance; Three dimensional test

Indexed keywords

AMIKACIN; BETA LACTAMASE AMPC; CEFALOTIN; CEFEPIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; PIPERACILLIN PLUS TAZOBACTAM;

AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BRAZIL; CONTROLLED STUDY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MULTIPLEX POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; UNIVERSITY HOSPITAL; URBAN AREA;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; BETA-LACTAMASES; BRAZIL; CLUSTER ANALYSIS; DNA FINGERPRINTING; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; GENOTYPE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POLYMERASE CHAIN REACTION; RANDOM AMPLIFIED POLYMORPHIC DNA TECHNIQUE;

EID: 37049033238     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2007.07.018     Document Type: Article

References (43)

1. Alves M.S., Dias R.C.S., Castro A.C.D., Riley L.W., and Moreira B.M. Identification of clinical isolates of indole-positive and indole-negative Klebsiella spp. J. Clin. Microbiol. 44 (2006) 3640-3646
2. Arakawa Y., Shibata N., Shibayama K., Kurokawa H., Yagi T., Fujiwara H., and Masafumi G. Convenient test for screening metallo-beta-lactamase-producing Gram-negative bacteria by using thiol compounds. J. Clin. Microbiol. 38 (2000) 40-43
3. Babini G.S., and Livermore D.M. Antimicrobial resistance amongst Klebsiella spp. Collected from intensive care unit in Southern and Western Europe in 1997-1998. J. Antimicrob. Chemother. 42 (2000) 183-189
4. Bell J.M., Turnidge J.D., Gales A.C., Pfaller M.A., and Jones R.N. Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn. Microbiol. Infect. Dis. 42 (2002) 193-198
5. Ben Redjeb S., Ben Yaghlane H., Boujnah A., Philippon A., and Labia R. Synergy between clavulanic acid and newer beta-lactams on nine clinical isolates of Klebsiella pneumoniae, Escherichia coli and Salmonella typhimurium resistant to third generation cephalosporins. J. Antimicrob. Chemother. 21 (1988) 263-266
6. Black J.J., Thomson K.S., and Pitout J.D.D. Use of beta-lactamase inhibitors in disk tests to detect plasmid-mediated AmpC beta-lactamases. J. Clin. Microbiol. 42 (2004) 2203-2206
7. Bobrowski M.M., Mthew M., Barth P.T., Datta N., Grinter N.J., Jacob A.E., Kontomichalou P., Dale J.W., and Smith J.T. Plasmid-determined beta-lactamase indistinguishable from the chromosomal beta-lactamase of Escherichia coli. J. Bacteriol. 123 (1976) 49-57
8. Bradford P.A. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14 (2001) 933-951
9. Bret L., Chanal-Claris C., Sirot D., Chaibi E.B., Labia R., and Sirot J. Chromosomally encoded AmpC-type beta-lactamase in a clinical isolate of Proteus mirabilis. Antimicrob. Agents Chemother. 42 (1998) 1110-1114
10. Clinical and Laboratory Standards Institute/NCCLS. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard-Seventh Edition. NCCLS document M2-A7 (2000), NCCLS, Wayne, PA 1-56238-393-0
11. Clinical and Laboratory Standards Institute/NCCLS. Performance standards for antimicrobial susceptibility testing; Fifteenth informational supplement. CLSI document M100-S15 (2005), Clinical and Laboratory Standards Institute, Wayne, PA. 1-56238-556-9
12. Cohen M.L. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 257 (1992) 1050-1055
13. Coudron P.E. Inhibitor-based methods for detection of plasmid-mediated AmpC beta-lactamases in Klebsiella spp., Escherichia coli, and Proteus mirabilis. J. Clin. Microbiol. 43 (2005) 4163-4167
14. Coudron P.E., Moland E.S., and Thomson K.S. Occurrence and detection of AmpC beta-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a Veterans Medical Center. J. Clin. Microbiol. 38 (2000) 1791-1796
15. Crompton I.E., Cuthbert B.K., Lowe G., and Waley S.G. Beta-lactamase inhibitors. The inhibition of serine beta-lactamases by specific boronic acids. Biochem. J. 251 (1988) 453-459
16. Dandekar P.K., Tetreault J., Quinn J.P., Nightingale C.H., and Nicolau D.P. Prevalence of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella isolates in a large community teaching hospital in Connecticut. Diagn. Microbiol. Infect. Dis. 49 (2004) 37-39
17. Davin-Regli A., Bosi C., Charrel R.N., Ageron E., Papazian L., Grimont P.A.D., Cremieux A., and Bollet C. A nosocomial outbreak due to Enterobacter cloacae strains with the E. hormaechei genotype in patients treated with fluoroquinolones. J. Clin. Microbiol. 35 (1997) 1008-1010
18. The Enterobacteriaceae. In: Winn Jr. W.C., Allen S.D., Janda W.M., Koneman E.W., Procop G.W., Schreckenberg P.C., and Woods G.L. (Eds). Koneman's color atlas and textbook of diagnostic microbiology. 6th ed. 6 (2006), Lippincott Williams & Wilkins, Philadelphia, EUA 213-308
19. Farmer III J.J. Enterobacteriaceae: introduction and identification. In: Murray P.R., Baron E.J., Jorgensen J.H., Pfaller M.A., and Yolken R.H. (Eds). Manual of clinical microbiology. 7th ed. 41 (2003), ASM Press, Washington, DC 636-653
20. Fluit A.C., Jones M.E., Schmitz F.J., Acar J., Gupta R., and Verhoef J. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin. Infect. Dis. 30 (2000) 454-460
21. Gazouli M., Tzouvelekis L.S., Vatopoulos A.C., and Tzelepi E. Transferable class C beta-lactamases in Escherichia coli strains isolated in Greek hospitals and characterization of two enzyme variants (LAT-3 and LAT-4) closely related to Citrobacter freundii AmpC beta-lactamase. J. Antimicrob. Chemother. 42 (1998) 419-425
22. Hanson N.D. AmpC beta-lactamases: what do we need to know for the future?. J. Antimicrob. Chemother. 52 (2003) 2-4
23. Hobson R.P., MacKenzie F.M., and Gould I.M. An outbreak of multiply-resistant Klebsiella pneumoniae in the Grampian region of Scotland. J. Hosp. Infect. 33 (1996) 249-262
24. Holmberg S., Solomon S., and Blake P. Health and economic impact of antimicrobial resistance. Rev. Infect. Dis. 9 (1987) 1065-1078
25. Jarlier V., Nicolas M.-H., Fournier G., and Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev. Infect. Dis. 10 (1988) 867-878
26. Jones R.N., and Pfaller M.A. Bacterial resistance: a worldwide problem. Diagn. Microbiol. Infect. Dis. 31 (1998) 379-388
27. Luzzaro F., Mezzatesta M., Mugnaioli C., Perilli M., Stefani S., Amicosante G., Rossolini G.M., and Toniolo A. Trends in production of extended-spectrum β-lactamases among enterobacteria of medical interest: report of the second Italian nationwide survey. J. Clin. Microbiol. 44 (2006) 1659-1664
28. Manchanda V., and Singh N.P. Occurrence and detection of AmpC beta-lactamases among Gram-negative clinical isolates using a modified three-dimensional test at Guru Tegh Bahadur Hospital, Delhi, India. J. Antimicrob. Chemother. 51 (2003) 415-418
29. Martínez-Martínez L., Pascual A., Hernández-Allés S., Alvarez-Díaz D., Suárez A.I., Tran J., Benedí V.J., and Jacoby G.A. Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob. Agents Chemother. 43 (1999) 1669-1673
30. Meyer K.S., Urban C., Eagan J.A., Berger B.J., and Rahal J.J. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann. Intern. Med. 119 (1993) 353-358
31. Pangon B., Bizet C., Bure A., Pichon F., Philippon A., Ragnier B., and Gutmann L. In vivo selection of a cephamycin-resistant, porin-deficient mutant of K. pneumoniae producing a TEM-3 beta-lactamase. J. Infect. Dis. 159 (1989) 1005-1006
32. Pérez-Pérez F.J., and Hanson N.D. Detection of plasmid-mediated AmpC beta-lactamase gene in clinical isolates by using multiplex PCR. J. Clin. Microbiol. 40 (2002) 2153-2162
33. Philippon A., Ben Redjeb S., Fournier G., and Ben Hassen A. Epidemiology of extended spectrum beta-lactamase. Infection 17 (1989) 347-354
34. Philippon A., Arlet G., and Jacoby G.A. Plasmid-determined AmpC-type beta-lactamases. Antimicrob. Agents Chemother. 46 (2002) 1-11
35. Ramchandani M., Manges A.R., DebRoy C., Smith S.P., Johnson J.R., and Riley L.W. Possible animal origin of human-associated, multidrug-resistant, uropathogenic Escherichia coli. Clin. Infect. Dis. 40 (2005) 251-257
36. Rice L.B., Willey S.H., Papanicolaou G.A., Medeiros A.A., Eliopoulos G.M., Moellering R.C., and Jacoby G.A. Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob. Agents Chemother. 34 (1990) 2193-2199
37. Schwaber M.J., Raney P.M., Rasheed J.K., Biddle J.W., Williams P., McGowan J.E., and Tenover F.C. Utility of NCCLS guidelines for identifying extended-spectrum beta-lactamases in non-Escherichia coli and non-Klebsiella spp Of Enterobacteriaceae. J. Clin. Microbiol. 42 (2004) 294-298
38. Thomson K.S. Controversies about extended-spectrum and AmpC beta-lactamases. Emerg. Infect. Dis. 7 (2001) 333-336
39. Verdet C., Arlet G., Ben Redjeb S., Ben Hassen A., Lagrange P.H., and Philippon A. Characterization of CMY-4, an AmpC-type plasmid-mediated beta-lactamase, in a Tunisian clinical isolate of Proteus mirabilis. FEMS Microbiol. Lett. 169 (1998) 235-240
40. Versalovic J., Koeuth T., and Lupski J.R. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. Nucleic Acids Res. 19 (1991) 6823-6831
41. Winokur P.L., Canton R., Casellas J.M., and Legakis N. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas and the Western Pacific region. Clin. Infect. Dis. 32 (2001) S94-S103
42. Yagi T., Wachino J.-I., Kurokawa H., Suzuki S., Yamane K., Doi Y., Shibata N., Kato H., Shibayama K., and Arakawa Y. Practical methods using boronic acid compounds for identification of class C beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. J. Clin. Microbiol. 43 (2005) 2151-2558
43. Yong D., Park R., Yum J.H., Lee K., Choi E.C., and Chong Y. Further modification of the Hodge test to screen AmpC beta-lactamase (CMY-1)-producing strains of Escherichia coli and Klebsiella pneumoniae. J. Microbiol. Methods 51 (2002) 407-410